NVS
Novartis AG
$
118.350
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
118.860
Open
118.070
VWAP
118.22
Vol
1.22M
Mkt Cap
246.82B
Low
117.950
Amount
144.26M
EV/EBITDA(TTM)
11.09
Total Shares
2.04B
EV
271.60B
EV/OCF(TTM)
13.07
P/S(TTM)
4.23
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
12.87B
-2.74%
1.950
-14.47%
13.58B
+3.26%
2.018
+1.89%
13.69B
+6.76%
2.294
+11.38%
Estimates Revision
The market is revising No Change the revenue expectations for Novartis AG (NVS) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 8.63%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+8.63%
In Past 3 Month
3 Analyst Rating
3.61% Upside
Wall Street analysts forecast NVS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVS is 122.62 USD with a low forecast of 108.00 USD and a high forecast of 137.24 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
3 Hold
0 Sell
Hold
3.61% Upside
Current: 118.350
Low
108.00
Averages
122.62
High
137.24
3.61% Upside
Current: 118.350
Low
108.00
Averages
122.62
High
137.24
Morgan Stanley
Underweight -> Equal Weight
upgrade
$110 -> $123
2025-08-08
New
Reason
Morgan Stanley
Price Target
$110 -> $123
2025-08-08
New
upgrade
Underweight -> Equal Weight
Reason
Morgan Stanley upgraded Novartis to Equal Weight from Underweight with a price target of $123, up from $110. The firm believes the company's valuation for growth is more attractive than Roche. Novartis' growth is now higher quality with less from Cosentyx, which is going off-patent in 2029, and its execution could continue to surprise to the upside, the analyst tells investors in a research note.
UBS
Matthew Weston
Strong Buy
to
Hold
Downgrades
n/a
2025-02-13
Reason
UBS
Matthew Weston
Price Target
n/a
2025-02-13
Downgrades
Strong Buy
to
Hold
Reason
UBS analyst Matthew Weston downgraded Novartis to Neutral from Buy with a price target of CHF 104, down from CHF 111. The firm believes the company's key growth drivers are already reflected in consensus expectations.
Erste Group
Hans Engel
Strong Buy
to
Hold
Downgrades
n/a
2024-11-19
Reason
Erste Group
Hans Engel
Price Target
n/a
2024-11-19
Downgrades
Strong Buy
to
Hold
Reason
Erste Group downgraded Novartis to Hold from Buy.
BMO Capital
Etzer Darout
Hold
Maintains
$118 → $120
2024-10-30
Reason
BMO Capital
Etzer Darout
Price Target
$118 → $120
2024-10-30
Maintains
Hold
Reason
B of A Securities
Graham Perry
Strong Buy
to
Hold
Downgrades
$135 → $130
2024-09-11
Reason
B of A Securities
Graham Perry
Price Target
$135 → $130
2024-09-11
Downgrades
Strong Buy
to
Hold
Reason
Goldman Sachs
James Quigley
Strong Buy
to
Hold
Downgrades
$119 → $121
2024-09-05
Reason
Goldman Sachs
James Quigley
Price Target
$119 → $121
2024-09-05
Downgrades
Strong Buy
to
Hold
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Novartis AG (NVS.N) is 13.46, compared to its 5-year average forward P/E of 13.56. For a more detailed relative valuation and DCF analysis to assess Novartis AG 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Fair
5Y Average PE
13.56
Current PE
13.46
Overvalued PE
15.53
Undervalued PE
11.59
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Undervalued
5Y Average EV/EBITDA
11.63
Current EV/EBITDA
10.72
Overvalued EV/EBITDA
12.48
Undervalued EV/EBITDA
10.77
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
3.97
Current PS
4.23
Overvalued PS
4.31
Undervalued PS
3.63
Financials
Annual
Quarterly
FY2025Q2
YoY :
+12.86%
14.53B
Total Revenue
FY2025Q2
YoY :
+22.81%
5.16B
Operating Profit
FY2025Q2
YoY :
+23.97%
4.02B
Net Income after Tax
FY2025Q2
YoY :
+29.56%
2.06
EPS - Diluted
FY2025Q2
YoY :
+47.24%
6.11B
Free Cash Flow
FY2025Q2
YoY :
+2.35%
77.15
Gross Profit Margin - %
FY2025Q2
YoY :
+28.42%
30.64
FCF Margin - %
FY2025Q2
YoY :
+9.83%
27.70
Net Margin - %
FY2025Q2
YoY :
-10.77%
20.04
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
16.4K
Volume
4
6-9
Months
362.5K
Volume
6
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
2
67.0K
Volume
Months
6-9
3
73.2K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
175.0K
USD
1
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
NVS News & Events
Events Timeline
2025-08-11 (ET)
2025-08-11
09:44:06
New
Novartis trial has positive read for Zura Bio, says Guggenheim
2025-08-11
05:30:36
Novartis announces both ianalumab trials met primary endpoint
2025-08-10 (ET)
2025-08-10
13:09:48
Swiss leaders to discuss tariff situation with Roche, Novartis, Bloomberg says
Sign Up For More Events
Sign Up For More Events
News
9.0
09:01 AMSeekingAlphaPinnedNovartis succeeds in late-stage Sjögren's disease trials
9.0
06:00 AMNASDAQ.COMPinnedNovartis' Ianalumab Meets Primary Endpoints In Phase III Trials For Sjögren's Disease
9.0
05:15 AMYahoo FinanceNovartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease
Sign Up For More News
People Also Watch
CAT
Caterpillar Inc
411.030
USD
-1.32%
QCOM
Qualcomm Inc
149.810
USD
+1.52%
GE
General Electric Co
275.100
USD
+0.03%
SHEL
Shell PLC
71.290
USD
-0.50%
LIN
Linde PLC
469.150
USD
-0.69%
HSBC
HSBC Holdings PLC
63.920
USD
+0.33%
ABT
Abbott Laboratories
131.780
USD
-1.86%
RY
Royal Bank of Canada
133.460
USD
+0.65%
VZ
Verizon Communications Inc
43.280
USD
+0.30%
TXN
Texas Instruments Inc
186.003
USD
-0.65%
FAQ
What is Novartis AG (NVS) stock price today?
The current price of NVS is 118.35 USD — it has increased 1.29 % in the last trading day.
What is Novartis AG (NVS)'s business?
What is the price predicton of NVS Stock?
What is Novartis AG (NVS)'s revenue for the last quarter?
What is Novartis AG (NVS)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Novartis AG (NVS)'s fundamentals?
How many employees does Novartis AG (NVS). have?